1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
Hidalgo, M.; Amant, F.; Biankin, A.V.; Budinská, E.; Byrne, A.T.; Caldas, C.; Clarke, R.B.; De Jong, S.; Jonkers, J.;
Mælandsmo, G.M.; et al. Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research.
Cancer Discov. 2014, 4, 998–1013. [CrossRef] [PubMed]
Gao, H.; Korn, J.M.; Ferretti, S.; Monahan, J.E.; Wang, Y.; Singh, M.; Zhang, C.; Schnell, C.; Yang, G.; Zhang, Y.; et al. Highthroughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat. Med. 2015, 21, 1318–1325.
[CrossRef] [PubMed]
Arrowsmith, J.; Miller, P.S. Phase II and Phase III attrition rates 2011–2012. Nat. Rev. Drug Discov. 2013, 12, 569. [CrossRef]
Arrowsmith, J. Phase II failures: 2008–2010. Nat. Rev. Drug Discov. 2011, 10, 328–329. [CrossRef]
DiMasi, J.A.; Reichert, J.M.; Feldman, L.; Malins, A. Clinical Approval Success Rates for Investigational Cancer Drugs. Clin.
Pharmacol. Ther. 2013, 94, 329–335. [CrossRef] [PubMed]
Amoedo, N.; Obre, E.; Rossignol, R. Drug discovery strategies in the field of tumor energy metabolism: Limitations by metabolic
flexibility and metabolic resistance to chemotherapy. Biochim. Biophys. Acta Bioenerg. 2017, 1858, 674–685. [CrossRef]
Kola, I.; Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 2004, 3, 711–716. [CrossRef]
Ravi, M.; Paramesh, V.; Kaviya, S.; Anuradha, E.; Solomon, F.P. 3D Cell Culture Systems: Advantages and Applications. J. Cell.
Physiol. 2015, 230, 16–26. [CrossRef]
Kondo, J.; Endo, H.; Okuyama, H.; Ishikawa, O.; Iishi, H.; Tsujii, M.; Ohue, M.; Inoue, M. Retaining cell-cell contact enables
preparation and culture of spheroids composed of pure primary cancer cells from colorectal cancer. Proc. Natl. Acad. Sci. USA
2011, 108, 6235–6240. [CrossRef] [PubMed]
Murakami, S.; Mukaisho, K.; Iwasa, T.; Kawabe, M.; Yoshida, S.; Taniura, N.; Nakayama, T.; Noi, M.; Yamamoto, G.; Sugihara, H.
Application of “Tissueoid Cell Culture System” Using a Silicate Fiber Scaffold for Cancer Research. Pathobiology 2020, 87, 291–301.
[CrossRef] [PubMed]
Noi, M.; Mukaisho, K.-I.; Yoshida, S.; Murakami, S.; Koshinuma, S.; Adachi, T.; Machida, Y.; Yamori, M.; Nakayama, T.;
Yamamoto, G.; et al. ERK phosphorylation functions in invadopodia formation in tongue cancer cells in a novel silicate fibrebased 3D cell culture system. Int. J. Oral Sci. 2018, 10, 30. [CrossRef]
International Agency for Research on Cancer. WHO Classification of Tumours of the Urinary System and Male Genital Organs, 4th ed.;
Moch, H., Reuter, V.E., Eds.; International Agency for Research on Cancer: Lyon, France, 2016.
Ritch, C.; Cookson, M. Recent trends in the management of advanced prostate cancer. F1000Research 2018, 7, 1513.
[CrossRef] [PubMed]
Bellmunt, J.; Orsola, A.; Leow, J.J.; Wiegel, T.; De Santis, M.; Horwich, A.; ESMO Guidelines Working Group. Bladder cancer:
ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2014, 25, iii40–iii48. [CrossRef] [PubMed]
King, J.L.; Jukes, T.H. Non-Darwinian Evolution. Science 1969, 164, 788–798. [CrossRef]
Int. J. Mol. Sci. 2021, 22, 1805
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
12 of 12
Vyas, S.; Zaganjor, E.; Haigis, M.C. Mitochondria and Cancer. Cell 2016, 166, 555–566. [CrossRef]
Warburg, O.; Posener, K.; Negelein, E. Über den stoffwechsel der carcinomzelle. Biochem. Z. 1924, 152, 319. [CrossRef]
Warburg, O. On the Origin of Cancer Cells. Science 1956, 123, 309–314. [CrossRef]
DeBerardinis, R.J.; Chandel, N.S. Fundamentals of cancer metabolism. Sci. Adv. 2016, 2, e1600200. [CrossRef]
Wallace, D.C. Mitochondria and cancer. Nat. Rev. Cancer 2012, 12, 685–698. [CrossRef] [PubMed]
Joshi, S.; Tolkunov, D.; Aviv, H.; Hakimi, A.A.; Yao, M.; Hsieh, J.J.; Ganesan, S.; Chan, C.S.; White, E. The Genomic Landscape of
Renal Oncocytoma Identifies a Metabolic Barrier to Tumorigenesis. Cell Rep. 2015, 13, 1895–1908. [CrossRef] [PubMed]
Weinberg, F.; Hamanaka, R.; Wheaton, W.W.; Weinberg, S.; Joseph, J.; Lopez, M.; Kalyanaraman, B.; Mutlu, G.M.; Budinger, G.R.S.;
Chandel, N.S. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc. Natl. Acad.
Sci. USA 2010, 107, 8788–8793. [CrossRef] [PubMed]
Martínez-Reyes, I.; Diebold, L.P.; Kong, H.; Schieber, M.; Huang, H.; Hensley, C.T.; Mehta, M.M.; Wang, T.; Santos, J.H.;
Woychik, R.; et al. TCA Cycle and Mitochondrial Membrane Potential Are Necessary for Diverse Biological Functions. Mol. Cell
2016, 61, 199–209. [CrossRef] [PubMed]
Krisher, R.L.; Prather, R.S. A role for the Warburg effect in preimplantation embryo development: Metabolic modification to
support rapid cell proliferation. Mol. Reprod. Dev. 2012, 79, 311–320. [CrossRef]
Yang, C.; Sudderth, J.; Dang, T.; Bachoo, R.G.; McDonald, J.G.; DeBerardinis, R.J. Glioblastoma Cells Require Glutamate
Dehydrogenase to Survive Impairments of Glucose Metabolism or Akt Signaling. Cancer Res. 2009, 69, 7986–7993. [CrossRef]
Intlekofer, A.M.; Finley, L.W.S. Metabolic signatures of cancer cells and stem cells. Nat. Metab. 2019, 1, 177–188. [CrossRef]
Murakami, S.; Tanaka, H.; Nakayama, T.; Taniura, N.; Miyake, T.; Tani, M.; Kushima, R.; Yamamoto, G.; Sugihara, H.; Mukaisho, K.
Similarities and differences in metabolites of tongue cancer cells among two- and three-dimensional cultures and xenografts.
Cancer Sci. 2020. [CrossRef]
Sahu, D.; Lotan, Y.; Wittmann, B.; Neri, B.; Hansel, D.E. Metabolomics analysis reveals distinct profiles of nonmuscle-invasive
and muscle-invasive bladder cancer. Cancer Med. 2017, 6, 2106–2120. [CrossRef]
Andrejeva, G.; Rathmell, J.C. Similarities and Distinctions of Cancer and Immune Metabolism in Inflammation and Tumors. Cell
Metab. 2017, 26, 49–70. [CrossRef] [PubMed]
Stincone, A.; Prigione, A.; Cramer, T.; Wamelink, M.M.C.; Campbell, K.; Cheung, E.; Olin-Sandoval, V.; Greuning, N.-M.;
Krueger, A.; Alam, M.T.; et al. The return of metabolism: Biochemistry and physiology of the pentose phosphate pathway. Biol.
Rev. 2015, 90, 927–963. [CrossRef] [PubMed]
Pampaloni, F.; Stelzer, E.H.; Masotti, A. Three-dimensional tissue models for drug discovery and toxicology. Recent Patents
Biotechnol. 2009, 3, 103–117. [CrossRef] [PubMed]
Loessner, D.; Stok, K.S.; Lutolf, M.P.; Hutmacher, D.W.; Clements, J.A.; Rizzi, S.C. Bioengineered 3D platform to explore cell–ECM
interactions and drug resistance of epithelial ovarian cancer cells. Biomaterials 2010, 31, 8494–8506. [CrossRef] [PubMed]
Nakamura, T.; Kato, Y.; Fuji, H.; Horiuchi, T.; Chiba, Y.; Tanaka, K. E-cadherin-dependent intercellular adhesion enhances
chemo-resistance. Int. J. Mol. Med. 2003, 12, 693–700. [PubMed]
Fan, T.W.-M.; El-Amouri, S.S.; Macedo, J.K.A.; Wang, Q.J.; Song, H.; Cassel, T.; Lane, A.N. Stable Isotope-Resolved Metabolomics
Shows Metabolic Resistance to Anti-Cancer Selenite in 3D Spheroids versus 2D Cell Cultures. Metabolites 2018, 8, 40.
[CrossRef] [PubMed]
Iwasa, T.; Watanabe, R.; Sasaki, K.; Matsushita, T.; Yamaguchi, A.; Kawabe, M. A culture method of rat hepatocytes using the
three-dimensional cell culture scaffold “Cellbed” and its application for liver toxicity testing. AATEX 2016, 21, 52–62.
Van Steenbrugge, G.J.; Groen, M.; Van Dogen, J.W.; Bolt, J.; Van Der Korput, H.; Trapman, J.; Hasenson, M.; Horoszewicz, J. The
human prostatic carcinoma cell line LNCaP and its derivatives: An overview. Urol. Res. 1989, 17, 71–77. [CrossRef] [PubMed]
Kaighn, M.E.; Narayan, K.S.; Ohnuki, Y.; Lechner, J.F.; Jones, L.W. Establishment and characterization of a human prostatic
carci-noma cell line (PC-3). Investig. Urol. 1979, 17, 16–23.
Grossman, H.B.; Wedemeyer, G.; Ren, L.; Wilson, G.N.; Cox, B. Improved Growth of Human Urothelial Carcinoma Cell Cultures.
J. Urol. 1986, 136, 953–959. [CrossRef]
...
論文の公開元へ
